RVXOT, thanks as always for your stimulating and very well researched posts.

Perhaps the answer is in todays SP and volumes. I'm finding it difficult to sit and watch while "the worlds leading epigenetic drug company" languishes as numerous other Canadian biotechs fly past RVX in terms of value creation and some were only founded 4 years ago (Repare Therapeutics). This week I read in the Globe about a BC biotech that is remaining private because they are generating lots of money.(I promise to do better research in the furure).

I find it completely unconscionable that the BOD decided to increase incentives to the CEO and business development VP. The CEO has talked for years about generating revenue from their blood sample data. No $ to date. No $ from anything. He also talked about "how quickly things move in cancer". And he seems to be correct because he is being surpassed by alternative biotechs that are actually creating value for their shareholders.

I still believe in the science and in the various scientific and medical posters on this board. This board is remarkable. We have all discussed the key issues in terms of lack of being able to capitalize on the value of these companies.

That being said, I must be nuts. It has been my understanding from reading Agora posts that Don made a significant commitment in China. Plus we have the Ori conversion of debt and IP ownership to shares and BTD. So given the declining share price I'm going to buy what ever I can afford next week although this time I am concerned that things may go south if option 1 is not achieved in December.

Thanks to all posters for your insight and depth of thought!

GLTA

Toinv